Design and synthesis of 4-O-methylhonokiol analogs as inhibitors of cyclooxygenase-2 (COX-2) and PGF 1 production

Bioorganic and Medicinal Chemistry

Volumn 20, Issue 9, 2012, Pages 2860-2868

  Lee, Bit ^a   Kwak, Jae Hwan ^b   Huang, Shin Won ^a   Jang, Jae Yong ^b   Lim, Sanglae ^a   Kwak, Young Shin ^c   Lee, Kiho ^c,d   Kim, Hyung Sook ^b   Han, Sang Bae ^b   Hong, Jin Tae ^b   Lee, Heesoon ^b   Song, Sukgil ^b   Seo, Seung Yong ^a   Jung, Jae Kyung ^b  

^a Woosuk University   (South Korea)

^b Chungbuk National University   (South Korea)

^c Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^d Korea University   (South Korea)

Author keywords

4 O Methylhonokiol; Aryl carbamate; Cyclooxygenase 2 (COX 2); Isoxazole; Triazole

Indexed keywords

2 (5 BROMO 2 METHOXYPHENYL) 5 PROPYLISOXAZOLE; 3 (5 ALLYL 2 METHOXYPHENYL) 5 PROPYLISOXAZOLE; 3',5 DIALLYL 2 ISOPROPOXY 4' METHOXY 1,1' BIPHENYL; 3',5 DIALLYL 2,4' DIMETHOXY 1,1' BIPHENYL; 3',5 DIALLYL 3 CHLORO 4' METHOXY [1,1' BIPHENYL] 2 OL; 3',5 DIALLYL 4' METHOXY 2[(3 METHYL 2 EN 1 YL)OXY] 1,1' BIPHENYL; 3',5 DIALLYL 4' METHOXY(1,1' BIPHENYL) 2 YL ACETATE; 3',5 DIALLYL 4' METHOXY(1,1' BIPHENYL) 2 YL ALLYLCARBAMATE; 3',5 DIALLYL 4' METHOXY(1,1' BIPHENYL) 2 YL BENZYL(METHYL)CARBAMATE; 3',5 DIALLYL 4' METHOXY(1,1' BIPHENYL) 2 YL BENZYLCARBAMATE; 4 ALLYL 2 (5 PROPYLISOXAZOL 3 YL)PHENOL; 4 ALLYL 2 [5 (HYDROXYMETHYL)ISOXAZOL 3 YL]PHENOL; 4 O METHYLHONOKIOL; 4 O METHYLHONOKIOL DERIVATIVE; 4' METHOXY 3',5 BIS(3 METHYLBUT 2 EN 1 YL)(1,1' BIPHENYL) 2 OL; 4' METHOXY 3',5 BIS(OXIRAN 2 YLMETHYL)(1,1' BIPHENYL) 2 OL; 5 ALLYL 3' (3 HYDROXYPROPYL) 4' METHOXY(1,1' BIPHENYL) 2 OL; [3 (5 ALLYL 2 METHOXYPHENYL)ISOXAZOL 5 YL]METHANOL; [3 (5 BROMO 2 METHOXYPHENYL)ISOXAZOL 5 YL]METHANOL; ALKENE; CELECOXIB; CYCLOOXYGENASE 2; ISOXAZOLE; LIGNAN DERIVATIVE; NITRIC OXIDE; PHENOL; PROSTAGLANDIN; PROSTAGLANDIN F1; TRIAZOLE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG DESIGN; DRUG STRUCTURE; DRUG SYNTHESIS; HALOGENATION; MACROPHAGE; PROSTAGLANDIN SYNTHESIS INHIBITION; STRUCTURE ACTIVITY RELATION;

ANIMALS; BIPHENYL COMPOUNDS; CELL LINE; CELL SURVIVAL; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DRUG DESIGN; ENZYME ACTIVATION; LIGNANS; MACROPHAGES; MICE; NITRIC OXIDE; PROSTAGLANDINS F; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84859893736     PISSN: 09680896     EISSN: 14643391     Source Type: Journal    
DOI: 10.1016/j.bmc.2012.03.028     Document Type: Article

References (27)

1. D.E. Griswold, and J.L. Adams Med. Res. Rev. 16 1996 181
2. R.N. DuBois, S.B. Abramson, L. Crofford, R.A. Gupta, L.S. Simon, L.B.A. Van De Putte, and P. Lipsky FASEB J. 12 1998 1063
3. G.A. FitzGerald Nat. Rev. Drug Disc. 2 2003 879
4. R.J. Flower Nat. Rev. Drug Disc. 2 2003 179
5. W.Z. Song, J.F. Cui, and G.D. Zhang Yao Xue Xue Bao 24 1989 295
6. F.S. El-Feraly, and W.-S. Li Lloydia 41 1978 442
7. K. Ito, T. Iida, K. Ichino, M. Tsunezuka, M. Hattori, and T. Namba Chem. Pharm. Bull. 30 1982 3347
8. K.V. Rao, and T.L. Davis Planta Med. 45 1982 57
9. Y. Maruyama, and H. Kuribara CNS Drug Rev. 6 2000 35
10. Y.K. Lee, D.Y. Yuk, T.I. Kim, Y.H. Kim, K.T. Kim, K.H. Kim, B.J. Lee, S.-Y. Nam, and J.T. Hong J. Natl. Med. Assoc. 63 2009 274
11. W. Schühly, S.I. Khan, and N.H. Fischer Inflammopharmacology 17 2009 106
12. J.H. Oh, L.L. Kang, J.O. Ban, Y.H. Kim, K.H. Kim, S.B. Han, and J.T. Hong Chem. Biol. Interact. 180 2009 506
13. Y.K. Lee, I.S. Choi, Y.H. Kim, K.H. Kim, S.Y. Nam, Y.W. Yun, M.S. Lee, K.W. Oh, and J.T. Hong Neurochem. Res. 34 2009 2251
14. J.W. Lee, Y.K. Lee, B.J. Lee, S.Y. Nam, S.I. Lee, Y.H. Kim, K.H. Kim, K.W. Oh, and J.T. Hong Pharmacol. Biochem. Behav. 95 2010 31
15. Y.K. Lee, I.S. Choi, J.O. Ban, H.J. Lee, U.S. Lee, S.B. Han, J.-K. Jung, Y.H. Kim, K.H. Kim, K.W. Oh, and J.T. Hong J. Nutr. Biochem. 50 2011 66
16. Y.-J. Lee, Y.M. Lee, C.K. Lee, J.-K. Jung, S.B. Han, and J.T. Hong Pharmacol. Ther. 130 2011 157 and references cited therein
17. W. Schühly, A. Hüfner, E.M. Pferschy-Wenzig, E. Prettner, M. Adams, A. Bodensieck, O. Kunert, A. Oluwemimo, E. Haslinger, and R. Bauer Bioorg. Med. Chem. 17 2009 4459
18. J.-H. Kwak, Y.A. Cho, J.-Y. Jang, S.-Y. Seo, H. Lee, J.T. Hong, S.-B. Han, K. Lee, Y.-S. Kwak, and J.-K. Jung Tetrahedron 67 2011 9401
19. Compounds 5, 8 and 14 were the known compounds; see Ref. 6.
20. K.J.P. Yoon, C.L. Morton, P.M. Potter, M.K. Danks, and R.E. Lee Bioorg. Med. Chem. 11 2003 3237
21. J.H. Kwak, J.K. In, M.S. Lee, E.H. Choi, H. Lee, J.T. Hong, Y.P. Yun, S.J. Lee, S.-Y. Seo, Y.-G. Suh, and J.-K. Jung Arch. Pharmacol. Res. 31 2008 1559
22. S. Tischer, and P. Metz Adv. Synth. Catal. 349 2007 147
23. D.A. Patrick, S.A. Bakunov, S.M. Bakunova, E.V.K.S. Kumar, R.J. Lombardy, S.K. Jones, A.S. Bridges, O. Zhirnov, J.E. Hall, T. Wenzler, R. Brun, and R.R. Tidwell J. Med. Chem. 50 2007 2468
24. A.K. Feldman, B. Colasson, and V.V. Fokin Org. Lett. 6 2004 3897
25. K. Kacprzak Synlett 2005 943
26. E.-Y. Chung, B.-H. Kim, I.-J. Lee, E. Roh, S.-J. Oh, J.-A. Kwak, Y.-R. Lee, B. Ahn, S.-Y. Nam, S.-B. Han, and Y. Kim Br. J. Pharmacol. 2009 1971 158
27. J.Y. Kim, J.S. Kang, H.M. Kim, H.S. Ryu, H.S. Kim, H.K. Lee, Y.J. Kim, J.T. Hong, Y. Kim, and S.-B. Han Int. Immunopharmacol. 10 2010 1185